# A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

> **NCT00838916** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 779 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** albiglutide
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT00838916
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-01
- **Final completion:** 2013-05
- **Target enrollment:** 779 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00838916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00838916, "A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00838916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*